A Two-Arm, Open-Label, Standard of Care Control Evaluation of Ferric Citrate for the Transition From Chronic Kidney Disease Stage 4/5 to Chronic Kidney Stage 5D

Trial Profile

A Two-Arm, Open-Label, Standard of Care Control Evaluation of Ferric Citrate for the Transition From Chronic Kidney Disease Stage 4/5 to Chronic Kidney Stage 5D

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 May 2017

At a glance

  • Drugs Ferric citrate (Primary)
  • Indications Hyperphosphataemia; Iron deficiency anaemia; Renal failure
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 May 2017 According to a Keryx Biopharmaceuticals media release, data from this study was presented at The National Kidney Foundations 2017 Spring Clinical Meetings and at the World Congress of Nephrology (WCN).
    • 05 Aug 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top